These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 1747725)

  • 41. Correlation between clinical response and urinary interleukin levels using different doses and intravesical administration schedules of interferon-alpha-2b combined with epirubicin: a pilot study.
    Serretta V; Corselli G; Piazza B; Lio D; Gervasi F; Salerno S; Pavone-Macaluso M
    Urol Res; 1993; 21(5):353-7. PubMed ID: 8279093
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intracavitary prophylactic treatment with interferon alpha 2b of patients with superficial bladder cancer is associated with a systemic T-cell activation.
    Molto L; Alvarez-Mon M; Carballido J; Manzano L; Guillen C; Prieto A; Olivier C; Rodriguez-Zapata M
    Br J Cancer; 1994 Dec; 70(6):1247-51. PubMed ID: 7981084
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Prophylaxis of superficial tumors of the bladder with interferon alfa-2B].
    Maffucci A; Fico A; Giannella L; Giannella R
    Arch Monaldi Mal Torace; 1990; 45(6):415-8. PubMed ID: 2152750
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Intravesical instillation of epirubicin in the prophylactic treatment of recurrent superficial bladder cancer].
    Kobayashi M; Sugaya Y; Yuzawa M; Morita T; Kobayashi Y; Tokue A
    Hinyokika Kiyo; 1998 Dec; 44(12):861-4. PubMed ID: 10028430
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intravesical immunoprophylaxis in recurrent superficial bladder cancer (Stage T1): multicenter trial comparing bacille Calmette-Guérin and interferon-alpha.
    Jimenez-Cruz JF; Vera-Donoso CD; Leiva O; Pamplona M; Rioja-Sanz LA; Martinez-Lasierra M; Flores N; Unda M
    Urology; 1997 Oct; 50(4):529-35. PubMed ID: 9338727
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Intravesical Bacillus Calmette-Guérin Versus Combination of Epirubicin and Interferon-α2a in Reducing Recurrence of Non-Muscle-invasive Bladder Carcinoma: FinnBladder-6 Study.
    Marttila T; Järvinen R; Liukkonen T; Rintala E; Boström P; Seppänen M; Tammela T; Hellström P; Aaltomaa S; Leskinen M; Raitanen M; Kaasinen E;
    Eur Urol; 2016 Aug; 70(2):341-7. PubMed ID: 27085624
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [BCG vs interferon A for prevention of recurrence of superficial bladder cancer. A prospective randomized study].
    Kälble T; Beer M; Mendoza E; Ikinger U; Link M; Reichert HE; Frangenheim T; Klein E; Fabricius PG
    Urologe A; 1994 Mar; 33(2):133-7. PubMed ID: 8178407
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intravesical ethoglucid (Epodyl) for treatment of noninvasive bladder cancer (stage Ta).
    Larson A; Fritjofsson A
    Ups J Med Sci; 1985; 90(2):127-32. PubMed ID: 3909592
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sustained prophylactic effect of intravesical bacille Calmette-Guérin for superficial bladder cancer: a smoothed hazard analysis in a randomized prospective study.
    Hinotsu S; Akaza H; Isaka S; Kanetake H; Kubota Y; Kuroda M; Shinohara N; Shinka T; Tachibana M; Naito S; Hirao Y;
    Urology; 2006 Mar; 67(3):545-9. PubMed ID: 16527576
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed.
    O'Donnell MA; Krohn J; DeWolf WC
    J Urol; 2001 Oct; 166(4):1300-4, discussion 1304-5. PubMed ID: 11547062
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up.
    Tolley DA; Parmar MK; Grigor KM; Lallemand G; Benyon LL; Fellows J; Freedman LS; Grigor KM; Hall RR; Hargreave TB; Munson K; Newling DW; Richards B; Robinson MR; Rose MB; Smith PH; Williams JL; Whelan P
    J Urol; 1996 Apr; 155(4):1233-8. PubMed ID: 8632538
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bacillus Calmette-Guérin plus intravesical interferon alpha-2b in patients with superficial bladder cancer.
    Stricker P; Pryor K; Nicholson T; Goldstein D; Golovsky D; Ferguson R; Nash P; Ehsman S; Rumma J; Mammen G; Penny R
    Urology; 1996 Dec; 48(6):957-61; discussion 961-2. PubMed ID: 8973689
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: interim report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party).
    Tolley DA; Hargreave TB; Smith PH; Williams JL; Grigor KM; Parmar MK; Freedman LS; Uscinska BM
    Br Med J (Clin Res Ed); 1988 Jun; 296(6639):1759-61. PubMed ID: 3136828
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Immunoprophylaxis of superficial tumors of the bladder with interferon alfa-2b. Our experience].
    Moyano Calvo JL; Teba del Pino F; Sanz Sacristán J; Fernández Arjona M; Arellano Gañan R; Rabadán Ruiz M; Herrero Torres L; Melón Rey FJ; Pereira Sanz I
    Arch Esp Urol; 1995; 48(1):55-9. PubMed ID: 7733688
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer.
    O'Donnell MA; Lilli K; Leopold C;
    J Urol; 2004 Sep; 172(3):888-93. PubMed ID: 15310991
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy of immediate instillation combined with regular instillations of pirarubicin for Ta and T1 transitional cell bladder cancer after transurethral resection: a prospective, randomized, multicenter study.
    Li NC; Ye ZQ; Na YQ;
    Chin Med J (Engl); 2013; 126(15):2805-9. PubMed ID: 23924446
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intravesical 4'-epi-doxorubicin (epirubicin) versus bacillus Calmette-Guérin. A controlled prospective study on the prophylaxis of superficial bladder cancer.
    Melekos MD; Chionis HS; Paranychianakis GS; Dauaher HH
    Cancer; 1993 Sep; 72(5):1749-55. PubMed ID: 8348504
    [TBL] [Abstract][Full Text] [Related]  

  • 58. 17-year follow-up of a randomized prospective controlled trial of adjuvant intravesical doxorubicin in the treatment of superficial bladder cancer.
    Cheng CW; Chan PS; Chan LW; Chan CK; Ng CF; Lai MM
    Int Braz J Urol; 2005; 31(3):204-11. PubMed ID: 15992422
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intravesical instillations of interferon gamma in the prophylaxis of high risk superficial bladder cancer--results of a controlled prospective study.
    Stavropoulos NE; Hastazeris K; Filiadis I; Mihailidis I; Ioachim E; Liamis Z; Kalomiris P
    Scand J Urol Nephrol; 2002; 36(3):218-22. PubMed ID: 12201939
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ultrastructural study of the noninvolved urothelium of tumor-bearing patients after two years of intravesical interferon therapy.
    Stravoravdi P; Natsis K; Kirtsis P; Retalis G; Konstandinidis E; Polyzonis M
    Eur Urol; 1996; 29(4):477-82. PubMed ID: 8791058
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.